Yanni Souroutzidis
Stock Analyst at Cantor Fitzgerald
(0.11)
# 4,731
Out of 5,065 analysts
10
Total ratings
n/a
Success rate
-57.6%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Yanni Souroutzidis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ELOX Eloxx Pharmaceuticals | Initiated Coverage: Buy | n/a | $13.06 | - | 1 | Oct 15, 2026 | |
| SGMT Sagimet Biosciences | Reiterated: Buy | $26 → $25 | $8.02 | +212.97% | 2 | Oct 1, 2026 | |
| POWL Powell Industries | Initiated Coverage: Hold | $235 | $165.14 | +42.30% | 1 | Sep 30, 2026 | |
| KPTI Karyopharm Therapeutics | Reiterated: Buy | $3.68 | $0.3901 | +843.35% | 3 | Sep 1, 2026 | |
| AGMB AgomAb Therapeutics NV | Initiated Coverage: Buy | $17 | $8.28 | +105.31% | 1 | Aug 19, 2026 | |
| TRDA Entrada Therapeutics | Initiated Coverage: Buy | n/a | $4.37 | - | 1 | Apr 1, 2026 | |
| TSX: MSCL Satellos Bioscience Inc. | Initiated Coverage: Buy | n/a | $9.25 | - | 1 | Mar 11, 2026 |
Eloxx Pharmaceuticals
Oct 15, 2026
Initiated Coverage: Buy
Price Target: n/a
Current: $13.06
Upside: -
Sagimet Biosciences
Oct 1, 2026
Reiterated: Buy
Price Target: $26 → $25
Current: $8.02
Upside: +212.97%
Powell Industries
Sep 30, 2026
Initiated Coverage: Hold
Price Target: $235
Current: $165.14
Upside: +42.30%
Karyopharm Therapeutics
Sep 1, 2026
Reiterated: Buy
Price Target: $3.68
Current: $0.3901
Upside: +843.35%
AgomAb Therapeutics NV
Aug 19, 2026
Initiated Coverage: Buy
Price Target: $17
Current: $8.28
Upside: +105.31%
Entrada Therapeutics
Apr 1, 2026
Initiated Coverage: Buy
Price Target: n/a
Current: $4.37
Upside: -
Satellos Bioscience Inc.
Mar 11, 2026
Initiated Coverage: Buy
Price Target: n/a
Current: $9.25
Upside: -